Pharmaceutical Executive-07-01-2022

Issue represents a potential threat in fighting future pandemics.

Pharma companies should review their commission-based compensation arrangements with independent contractors to address enforcement risk under the Anti-Kickback Statute, in light of recent Department of Justice enforcement.

With heightened government scrutiny on educational forums, biopharma manufacturers need a sound framework that demonstrates they are following best practices.

A proactive and tailored compliance department—with the nimbleness to adapt strategies on the fly—is a critical shield for life sciences companies during government investigations.

COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a key strategic cog.

Dealing with discrimination and bias throughout her career, Otsuka Pharmaceutical’s Christine Sakdalan has forged a strong leadership path built around a two-pronged mission—finding true meaning in the patient journey through market research and data analytics, and mentoring and supporting the development of today’s aspiring professionals.

A summary of key takeaways from EY’s new Beyond Borders report.

Reversing non-formulary status will usually require new data.

For industries like pharma, company voices are vital to building trust.

Continent has shed its ‘emerging’ status on world biopharma stage.

Legislative-reform alliance makes for strange bedfellows.

Pharm Exec introduces new members to EAB.

Click the title above for a link to open the Pharmaceutical Executive July 2022 issue in an interactive PDF format.

Larger pipeline and increased support from regulatory authorities are setting up the orphan drug market for long-term success.

Agency again pursuing manufacturer rating system.